Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CDRH's Innovation Pathway: A Quicker Route For Breakthrough Devices?

This article was originally published in The Gray Sheet

Executive Summary

For a select few devices per year, FDA says it will speed up pre-market development times by intensifying staff efforts, with a particular focus on very early-stage, frequent interactions with product sponsors.

Related Content

Start-Up FDA? CDRH Seeks Entrepreneurial Spirit With New “In-Residence” Program
FDA Outlines Next Steps In Regulatory Science
FDA 'Entrepreneurs-In-Residence' Program Aims To Help Small Companies
Industry Questions On CDRH Reform Plans Hold Up User Fee Progress
Group Calls For Public-Private Partnership To Develop Value-Driven Devices
Innovation Pathway? Why Not Fix Expedited Review, AdvaMed Suggests
Shuren: Budget Woes Will Have Big Impact On FDA Device Center
Innovation Efforts Offer A Way To Change FDA's Views On Risk, Industry Says
U.S. Could Speed Device Innovation Through Clinical Research Reforms
Device Innovation: Report Paints Dire Picture; Prez, FDA Take "Positive" Steps





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts